Practice
Open Access
Nirmatrelvir-ritonavir for COVID-19
Emily G McDonald and Todd C Lee
CMAJ February 14, 2022 194 (6) E218; DOI: https://doi.org/10.1503/cmaj.220081
Emily G McDonald
Clinical Practice Assessment Unit (McDonald, Lee), and Divisions of Internal Medicine (McDonald) and Infectious Diseases (Lee), Department of Medicine, McGill University Health Centre, Montréal, Que.
MD MScTodd C Lee
Clinical Practice Assessment Unit (McDonald, Lee), and Divisions of Internal Medicine (McDonald) and Infectious Diseases (Lee), Department of Medicine, McGill University Health Centre, Montréal, Que.
MD MPHData supplements
Related Articles
- McDonald, E. G., & Lee, T. C. (2022). Association nirmatrelvir/ritonavir contre la COVID-19. CMAJ, 194(9), E365-E366. Accessed April 17, 2024. https://doi.org/10.1503/cmaj.220081-f.
- Hiremath, S. (2022). Renalism. CMAJ, 194(29), E1040. Accessed April 17, 2024. https://doi.org/10.1503/cmaj.146430-l.
In this issue
Article tools
Respond to this article
Nirmatrelvir-ritonavir for COVID-19
Emily G McDonald, Todd C Lee
CMAJ Feb 2022, 194 (6) E218; DOI: 10.1503/cmaj.220081
Jump to section
- Article
- Ritonavir-boosted nirmatrelvir (marketed as Paxlovid) is a Health Canada–approved oral antiviral medication with activity against SARS-CoV-2
- Studies recruited primarily unvaccinated participants, predated the omicron variant and have not yet undergone peer review
- The treatment is copackaged as nirmatrelvir (300 mg — two 150 mg tablets) with ritonavir (one 100 mg tablet); the 3 tablets are taken together twice daily for 5 days
- The ritonavir component boosts nirmatrelvir levels and is a cytochrome P450 3A4 (CYP3A4) inhibitor when taken short term, leading to important drug–drug interactions5
- Mitigation strategies for drug–drug interactions include dose reductions, switching or temporarily holding a drug, and therapeutic drug monitoring
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics